NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Price Target & More

$100.73 -0.76 (-0.75 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$101.49
Today's Range$100.62 - $102.12
52-Week Range$93.01 - $128.46
Volume33,228 shs
Average Volume90,046 shs
Market Capitalization$4.09 billion
P/E Ratio9.11
Dividend YieldN/A
Beta0.62

About Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TARO
CUSIPN/A
Phone972-4847-5700

Debt

Debt-to-Equity RatioN/A
Current Ratio8.93%
Quick Ratio8.23%

Price-To-Earnings

Trailing P/E Ratio9.11
Forward P/E Ratio19.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$879.39 million
Price / Sales4.59
Cash Flow$11.4989 per share
Price / Cash8.76
Book Value$51.19 per share
Price / Book1.97

Profitability

EPS (Most Recent Fiscal Year)$11.06
Net Income$456.35 million
Net Margins30.43%
Return on Equity11.35%
Return on Assets10.33%

Miscellaneous

EmployeesN/A
Outstanding Shares40,100,000

How to Become a New Pot Stock Millionaire

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings results on Wednesday, February, 7th. The company reported $1.37 earnings per share for the quarter. The business had revenue of $155.46 million for the quarter. Taro Pharmaceutical Industries had a net margin of 30.43% and a return on equity of 11.35%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Monday, May, 28th 2018. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

2 Wall Street analysts have issued 12 month target prices for Taro Pharmaceutical Industries' shares. Their predictions range from $124.00 to $124.00. On average, they expect Taro Pharmaceutical Industries' share price to reach $124.00 in the next year. View Analyst Ratings for Taro Pharmaceutical Industries.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Michael Perfetto, Group VP (Age 57)
  • Mr. Ara Aprahamian, Exec. Officer
  • Mr. Uday V. Baldota, CEO & Director (Age 48)
  • Mr. Mariano Balaguer, VP, CFO & Chief Accounting Officer (Age 45)
  • Mr. Jeff Holm, Exec. Director Sales and Operations

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News articles about TARO stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 45.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $100.73.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $4.09 billion and generates $879.39 million in revenue each year. The company earns $456.35 million in net income (profit) each year or $11.06 on an earnings per share basis.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (TARO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Taro Pharmaceutical Industries (NYSE:TARO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Taro Pharmaceutical Industries in the last 12 months. Their average twelve-month price target is $124.00, suggesting that the stock has a possible upside of 23.10%. The high price target for TARO is $124.00 and the low price target for TARO is $124.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $124.00$124.00N/AN/A
Price Target Upside: 23.10% upside23.78% upsideN/AN/A

Taro Pharmaceutical Industries (NYSE:TARO) Consensus Price Target History

Price Target History for Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries (NYSE:TARO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018HC WainwrightSet Price TargetBuy$124.00MediumView Rating Details
5/23/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Taro Pharmaceutical Industries (NYSE:TARO) Earnings History and Estimates Chart

Earnings by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries (NYSE:TARO) Earnings Estimates

Current Year EPS Consensus Estimate: $5.28 EPS
Next Year EPS Consensus Estimate: $8.55 EPS

Taro Pharmaceutical Industries (NYSE TARO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018N/AView Earnings Details
2/7/2018Q3 2018$1.37$155.46 millionViewN/AView Earnings Details
11/7/2017Q2 2018$1.30$169.92 millionViewN/AView Earnings Details
8/8/2017Q1 2018$1.35$161.32 millionViewN/AView Earnings Details
5/22/2017Q4$2.05$196.41 millionViewN/AView Earnings Details
2/9/2017Q3 2017$3.42$220.40 millionViewN/AView Earnings Details
11/8/2016Q2 2017$3.00$228.79 millionViewListenView Earnings Details
8/10/2016Q1$2.59$215.30 million$233.80 millionViewN/AView Earnings Details
5/26/2016Q4$2.68$265.07 millionViewListenView Earnings Details
2/10/2016Q316$4.41$974.38 million$258.30 millionViewN/AView Earnings Details
11/3/2015Q2 2016$3.11$212.06 millionViewN/AView Earnings Details
8/6/2015Q116$2.42$1.01 billion$215.30 millionViewN/AView Earnings Details
5/26/2015Q415$3.56$881.79 million$244.18 millionViewListenView Earnings Details
2/10/2015Q315$3.33$213.60 million$237.70 millionViewN/AView Earnings Details
11/9/2014Q2 2015$3.35$250.83 millionViewN/AView Earnings Details
8/7/2014Q1 2015$0.98$130.23 millionViewN/AView Earnings Details
5/27/2014Q4$5.93$2.10$165.13 million$187.20 millionViewN/AView Earnings Details
2/10/2014Q214$2.59$185.70 million$213.60 millionViewN/AView Earnings Details
11/12/2013Q3$2.15$205.32 millionViewN/AView Earnings Details
8/7/2013Q114$1.32$159.15 million$153.20 millionViewN/AView Earnings Details
5/23/2013Q4 2013$1.10$145.00 million$165.10 millionViewN/AView Earnings Details
2/4/2013Q3 2013$1.98ViewN/AView Earnings Details
11/1/2012Q213$1.46$138.25 million$160.97 millionViewN/AView Earnings Details
8/6/2012Q1 2013$1.41ViewN/AView Earnings Details
5/24/2012Q4 2012$1.06ViewN/AView Earnings Details
2/10/2012Q3 2012$1.42ViewN/AView Earnings Details
11/10/2011Q2 2012$1.31ViewN/AView Earnings Details
7/26/2011Q1 2012$0.81ViewN/AView Earnings Details
5/26/2011Q4 2011$0.58ViewN/AView Earnings Details
1/28/2011Q3 2011$0.11ViewN/AView Earnings Details
10/29/2010Q2 2011$0.46ViewN/AView Earnings Details
8/23/2010Q1 2011$0.46ViewN/AView Earnings Details
6/14/2010Q4 2010$0.25ViewN/AView Earnings Details
12/2/2009Q2 2010$0.24ViewN/AView Earnings Details
8/10/2009Q1 2010$0.31ViewN/AView Earnings Details
5/22/2009Q4 2009$0.27ViewN/AView Earnings Details
2/10/2009Q3 2009$0.65ViewN/AView Earnings Details
11/11/2008Q2 2009$0.31ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Taro Pharmaceutical Industries (NYSE:TARO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Taro Pharmaceutical Industries (NYSE TARO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 12.49%
Insider Trading History for Taro Pharmaceutical Industries (NYSE:TARO)
Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries (NYSE TARO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Taro Pharmaceutical Industries (NYSE TARO) News Headlines

Source:
DateHeadline
ACETO Board Takes Proactive Steps to Address Business and Financial ChallengesACETO Board Takes Proactive Steps to Address Business and Financial Challenges
globenewswire.com - April 18 at 5:06 PM
Zacks: Brokerages Set $124.00 Price Target for Taro Pharmaceutical Industries Ltd. (TARO)Zacks: Brokerages Set $124.00 Price Target for Taro Pharmaceutical Industries Ltd. (TARO)
www.americanbankingnews.com - April 14 at 5:09 PM
At $97.85, Is Taro Pharmaceutical Industries Ltd (NYSE:TARO) A Buy?At $97.85, Is Taro Pharmaceutical Industries Ltd (NYSE:TARO) A Buy?
finance.yahoo.com - April 4 at 3:38 PM
Taro Pharmaceutical Industries (TARO) Given a $124.00 Price Target at HC WainwrightTaro Pharmaceutical Industries (TARO) Given a $124.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 2 at 9:34 AM
Brokerages Anticipate Taro Pharmaceutical Industries Ltd. (TARO) to Announce $2.22 Earnings Per ShareBrokerages Anticipate Taro Pharmaceutical Industries Ltd. (TARO) to Announce $2.22 Earnings Per Share
www.americanbankingnews.com - March 30 at 3:38 AM
Crescita Announces Launch of Pliaglis in U.S.Crescita Announces Launch of Pliaglis in U.S.
finance.yahoo.com - March 29 at 9:18 AM
Brokerages Anticipate Taro Pharmaceutical Industries Ltd. (TARO) to Post $2.22 Earnings Per ShareBrokerages Anticipate Taro Pharmaceutical Industries Ltd. (TARO) to Post $2.22 Earnings Per Share
www.americanbankingnews.com - March 26 at 1:28 PM
Should You Be Tempted To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO) Because Of Its PE Ratio?Should You Be Tempted To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO) Because Of Its PE Ratio?
finance.yahoo.com - March 23 at 4:56 PM
 Analysts Set $124.00 Target Price for Taro Pharmaceutical Industries Ltd. (TARO) Analysts Set $124.00 Target Price for Taro Pharmaceutical Industries Ltd. (TARO)
www.americanbankingnews.com - March 23 at 3:34 PM
Zacks: Taro Pharmaceutical Industries Ltd. (TARO) Given $124.00 Consensus Price Target by BrokeragesZacks: Taro Pharmaceutical Industries Ltd. (TARO) Given $124.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - March 19 at 5:52 AM
Taro Pharmaceutical Industries (TARO) Stock Rating Upgraded by ValuEngineTaro Pharmaceutical Industries (TARO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Zacks: Taro Pharmaceutical Industries Ltd. (TARO) Given $124.00 Consensus Target Price by AnalystsZacks: Taro Pharmaceutical Industries Ltd. (TARO) Given $124.00 Consensus Target Price by Analysts
www.americanbankingnews.com - March 13 at 5:30 PM
Taro Pharmaceutical Industries (TARO) Receives New Coverage from Analysts at HC WainwrightTaro Pharmaceutical Industries (TARO) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - March 12 at 8:48 PM
Apricus Biosciences (APRI) and Taro Pharmaceutical Industries (TARO) Head-To-Head ReviewApricus Biosciences (APRI) and Taro Pharmaceutical Industries (TARO) Head-To-Head Review
www.americanbankingnews.com - March 3 at 10:34 AM
Taro Pharmaceutical Industries Ltd. (TARO) Position Increased by Brandes Investment Partners LPTaro Pharmaceutical Industries Ltd. (TARO) Position Increased by Brandes Investment Partners LP
www.americanbankingnews.com - February 28 at 5:16 AM
Arrowstreet Capital Limited Partnership Invests $11.09 Million in Taro Pharmaceutical Industries Ltd. (TARO)Arrowstreet Capital Limited Partnership Invests $11.09 Million in Taro Pharmaceutical Industries Ltd. (TARO)
www.americanbankingnews.com - February 28 at 4:42 AM
Taro Pharmaceutical Industries Ltd. (TARO) is Fort L.P.s 9th Largest PositionTaro Pharmaceutical Industries Ltd. (TARO) is Fort L.P.'s 9th Largest Position
www.americanbankingnews.com - February 27 at 3:36 PM
Where Taro Pharmaceutical Industries Ltd (NYSE:TARO) Stands In Terms Of Earnings Growth Against Its IndustryWhere Taro Pharmaceutical Industries Ltd (NYSE:TARO) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - February 20 at 8:48 AM
Taro Provides Results for December 31, 2017Taro Provides Results for December 31, 2017
finance.yahoo.com - February 9 at 4:45 PM
Taro to Announce Third Quarter Results on February 7, 2018Taro to Announce Third Quarter Results on February 7, 2018
finance.yahoo.com - February 1 at 9:31 AM
Taro Pharmaceutical Industries (TARO) Set to Announce Quarterly Earnings on WednesdayTaro Pharmaceutical Industries (TARO) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:48 AM
Short Interest in Taro Pharmaceutical Industries Ltd. (TARO) Decreases By 42.2%Short Interest in Taro Pharmaceutical Industries Ltd. (TARO) Decreases By 42.2%
www.americanbankingnews.com - January 4 at 1:16 AM
Is It Too Late To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO)?Is It Too Late To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO)?
finance.yahoo.com - January 3 at 3:36 PM
How Taro Pharmaceutical Industries Ltd (NYSE:TARO) Delivered A Better ROE Than Its IndustryHow Taro Pharmaceutical Industries Ltd (NYSE:TARO) Delivered A Better ROE Than Its Industry
finance.yahoo.com - December 26 at 8:36 PM
Contrasting Taro Pharmaceutical Industries (TARO) & Neuralstem (CUR)Contrasting Taro Pharmaceutical Industries (TARO) & Neuralstem (CUR)
www.americanbankingnews.com - December 26 at 9:24 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 20, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 20, 2017
finance.yahoo.com - December 20 at 3:35 PM
Critical Survey: Collegium Pharmaceutical (COLL) & Taro Pharmaceutical Industries (TARO)Critical Survey: Collegium Pharmaceutical (COLL) & Taro Pharmaceutical Industries (TARO)
www.americanbankingnews.com - December 14 at 7:16 AM
Head-To-Head Review: Taro Pharmaceutical Industries (TARO) versus Veru (VERU)Head-To-Head Review: Taro Pharmaceutical Industries (TARO) versus Veru (VERU)
www.americanbankingnews.com - December 3 at 8:14 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 1, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 1, 2017
finance.yahoo.com - December 1 at 5:01 PM
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 12:08 PM
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : November 24, 2017Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : November 24, 2017
finance.yahoo.com - November 24 at 6:14 PM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : November 23, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : November 23, 2017
finance.yahoo.com - November 23 at 4:21 PM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : November 16, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : November 16, 2017
finance.yahoo.com - November 18 at 9:10 AM
Taro Pharmaceutical Industries Earns RS Rating UpgradeTaro Pharmaceutical Industries Earns RS Rating Upgrade
finance.yahoo.com - November 14 at 8:29 AM
Taro Provides Results for September 30, 2017 | Business Wire - Business Wire (press release)Taro Provides Results for September 30, 2017 | Business Wire - Business Wire (press release)
www.businesswire.com - November 9 at 2:23 PM
Taro Pharmaceutical Industries (TARO) CEO Uday Vijaykumar Baldota on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaTaro Pharmaceutical Industries' (TARO) CEO Uday Vijaykumar Baldota on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 2:23 PM
Edited Transcript of TARO earnings conference call or presentation 8-Nov-17 1:00pm GMTEdited Transcript of TARO earnings conference call or presentation 8-Nov-17 1:00pm GMT
finance.yahoo.com - November 9 at 2:23 PM
Taro Pharmaceutical Industries Ltd.: Leads amongst peers with strong fundamentalsTaro Pharmaceutical Industries Ltd.: Leads amongst peers with strong fundamentals
finance.yahoo.com - November 9 at 2:23 PM
Financial Survey: Taro Pharmaceutical Industries (TARO) versus Akorn (AKRX)Financial Survey: Taro Pharmaceutical Industries (TARO) versus Akorn (AKRX)
www.americanbankingnews.com - November 7 at 11:10 PM
Taro to Announce Second Quarter Results on November 7, 2017Taro to Announce Second Quarter Results on November 7, 2017
finance.yahoo.com - October 31 at 10:21 AM
Taro Pharmaceutical Industries Ltd. (TARO) to Release Earnings on MondayTaro Pharmaceutical Industries Ltd. (TARO) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
Contrasting Taro Pharmaceutical Industries (TARO) and Its PeersContrasting Taro Pharmaceutical Industries (TARO) and Its Peers
www.americanbankingnews.com - October 29 at 1:08 AM
Contrasting Taro Pharmaceutical Industries (TARO) and The CompetitionContrasting Taro Pharmaceutical Industries (TARO) and The Competition
www.americanbankingnews.com - October 22 at 2:08 PM
Shares of large generic drugmakers fallShares of large generic drugmakers fall
www.marketwatch.com - October 19 at 9:36 AM
Shares of large generic drugmakers fallShares of large generic drugmakers fall
www.marketwatch.com - October 19 at 9:36 AM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : October 19, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : October 19, 2017
finance.yahoo.com - October 19 at 9:36 AM
Taro Pharmaceutical Industries Ltd. (TARO) Downgraded to Hold at BidaskClubTaro Pharmaceutical Industries Ltd. (TARO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - October 15 at 2:06 PM
Does Taro Pharmaceutical Industries Ltd’s (TARO) PE Ratio Signal A Buying Opportunity?Does Taro Pharmaceutical Industries Ltd’s (TARO) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - September 30 at 6:36 PM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : September 22, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : September 22, 2017
finance.yahoo.com - September 23 at 9:50 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 9:37 AM

SEC Filings

Taro Pharmaceutical Industries (NYSE:TARO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Taro Pharmaceutical Industries (NYSE:TARO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Taro Pharmaceutical Industries (NYSE TARO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.